Each patient is also different to androgen blockade treatment. A portion of patients quickly lose their effect on treatment during the course of treatment and the disease progresses rapidly. For these patients, our team at Changhai Hospital has conducted a lot of research and discovered some new molecules and genetic indicators in blood and tissues that can identify these special patients as early as possible, and can provide individualized treatment recommendations through relevant tests. We believe that only such individualized “precise” treatment can bring better results to patients. Prostate cancer after the “failure” of androgen blockade therapy is currently a hot topic of academic research. In recent years, some new drugs and therapies have been introduced in this field. Chemotherapy, represented by docetaxel, can significantly extend the median survival of patients by 2-2.5 months; MDV3100, a new anti-androgen drug, can improve survival by 4.8 months on average; immunotherapy with autologous vaccine can improve survival by 4.1 months; these drugs have entered or will enter clinical application in China. In conclusion, prostate cancer itself is not a terrible disease. Through a comprehensive evaluation of the disease and the necessary clinical examination, a professional and responsible doctor will certainly be able to choose an appropriate treatment for the patient, so that most patients can get a good treatment result.